Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Linking SOX10 to a slow-growth resistance phenotype.

Literature DB >> 24853952

Linking SOX10 to a slow-growth resistance phenotype.

Abstract

Slow-cycling BRAF melanoma cells are notoriously resistant to standard chemotherapy or targeted therapy but the underlying mechanism remains elusive. Now a new study unlocks this mystery and offers novel insights into developing more effective therapeutic interventions.

Entities: Disease Gene

Mesh：

Substances：

Year: 2014 PMID： 24853952 PMCID： PMC4123291 DOI： 10.1038/cr.2014.67

Source DB: PubMed Journal: Cell Res ISSN： 1001-0602 Impact factor: 25.617

10 in total

1. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors: Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal: Nature Date: 2012-01-26 Impact factor: 49.962

2. Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal: N Engl J Med Date: 2010-08-26 Impact factor: 91.245

3. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.

Authors: Ethan V Abel; Kevin J Basile; Curtis H Kugel; Agnieszka K Witkiewicz; Kaitlyn Le; Ravi K Amaravadi; Giorgos C Karakousis; Xiaowei Xu; Wei Xu; Lynn M Schuchter; Jason B Lee; Adam Ertel; Paolo Fortina; Andrew E Aplin
Journal: J Clin Invest Date: 2013-04-01 Impact factor: 14.808

4. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Authors: Chong Sun; Liqin Wang; Sidong Huang; Guus J J E Heynen; Anirudh Prahallad; Caroline Robert; John Haanen; Christian Blank; Jelle Wesseling; Stefan M Willems; Davide Zecchin; Sebastijan Hobor; Prashanth K Bajpe; Cor Lieftink; Christina Mateus; Stephan Vagner; Wipawadee Grernrum; Ingrid Hofland; Andreas Schlicker; Lodewyk F A Wessels; Roderick L Beijersbergen; Alberto Bardelli; Federica Di Nicolantonio; Alexander M M Eggermont; Rene Bernards
Journal: Nature Date: 2014-03-26 Impact factor: 49.962

5. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Authors: Jessie Villanueva; Adina Vultur; John T Lee; Rajasekharan Somasundaram; Mizuho Fukunaga-Kalabis; Angela K Cipolla; Bradley Wubbenhorst; Xiaowei Xu; Phyllis A Gimotty; Damien Kee; Ademi E Santiago-Walker; Richard Letrero; Kurt D'Andrea; Anitha Pushparajan; James E Hayden; Kimberly Dahlman Brown; Sylvie Laquerre; Grant A McArthur; Jeffrey A Sosman; Katherine L Nathanson; Meenhard Herlyn
Journal: Cancer Cell Date: 2010-12-14 Impact factor: 31.743

6. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors: Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal: Nature Date: 2010-11-24 Impact factor: 49.962

7. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.

Authors: David J Konieczkowski; Cory M Johannessen; Omar Abudayyeh; Jong Wook Kim; Zachary A Cooper; Adriano Piris; Dennie T Frederick; Michal Barzily-Rokni; Ravid Straussman; Rizwan Haq; David E Fisher; Jill P Mesirov; William C Hahn; Keith T Flaherty; Jennifer A Wargo; Pablo Tamayo; Levi A Garraway
Journal: Cancer Discov Date: 2014-04-25 Impact factor: 39.397

8. Vemurafenib induces senescence features in melanoma cells.

Authors: Sebastian Haferkamp; Andreas Borst; Christian Adam; Therese M Becker; Stephanie Motschenbacher; Simone Windhövel; Anita L Hufnagel; Roland Houben; Svenja Meierjohann
Journal: J Invest Dermatol Date: 2013-02-14 Impact factor: 8.551

9. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Authors: Hubing Shi; Willy Hugo; Xiangju Kong; Aayoung Hong; Richard C Koya; Gatien Moriceau; Thinle Chodon; Rongqing Guo; Douglas B Johnson; Kimberly B Dahlman; Mark C Kelley; Richard F Kefford; Bartosz Chmielowski; John A Glaspy; Jeffrey A Sosman; Nicolas van Baren; Georgina V Long; Antoni Ribas; Roger S Lo
Journal: Cancer Discov Date: 2013-11-21 Impact factor: 39.397

10. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.

Authors: Cory M Johannessen; Laura A Johnson; Federica Piccioni; Aisha Townes; Dennie T Frederick; Melanie K Donahue; Rajiv Narayan; Keith T Flaherty; Jennifer A Wargo; David E Root; Levi A Garraway
Journal: Nature Date: 2013-11-03 Impact factor: 49.962